Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases
- 05.02.2024
- Leading Article
- Verfasst von
-
Giulio Napolitano
Korrespondierender Autor Giulio Napolitano
- Centogene GmbH, 12103, Berlin, Germany
-
Canan Has
Canan Has
- Centogene GmbH, 12103, Berlin, Germany
-
Anne Schwerk
Anne Schwerk
- Beriln Institute of Health Center for Regenerative Therapies (BCRT), Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Berlin, Germany
-
Jui-Hung Yuan
Jui-Hung Yuan
- Beriln Institute of Health Center for Regenerative Therapies (BCRT), Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Berlin, Germany
-
Carsten Ullrich
Carsten Ullrich
- Beriln Institute of Health Center for Regenerative Therapies (BCRT), Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Erschienen in
- Pharmaceutical Medicine | Ausgabe 2/2024
Abstract
The growth in breadth and depth of artificial intelligence (AI) applications has been fast, running hand in hand with the increasing amount of digital data available. Here, we comment on the application of AI in the field of drug development, with a strong focus on the specific achievements and challenges posed by rare diseases. Data paucity and high costs make drug development for rare diseases especially hard. AI can enable otherwise inaccessible approaches based on the large-scale integration of heterogeneous datasets and knowledge bases, guided by expert biological understanding. Obstacles still exist for the routine use of AI in the usually conservative pharmaceutical domain, which can easily become disillusioned. It is crucial to acknowledge that AI is a powerful, supportive tool that can assist but not replace human expertise in the various phases and aspects of drug discovery and development.
Anzeige
- Titel
- Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases
- Verfasst von
-
Giulio Napolitano
Canan Has
Anne Schwerk
Jui-Hung Yuan
Carsten Ullrich
- Publikationsdatum
- 05.02.2024
- Verlag
- Springer International Publishing
- Erschienen in
-
Pharmaceutical Medicine / Ausgabe 2/2024
Print ISSN: 1178-2595
Elektronische ISSN: 1179-1993 - DOI
- https://doi.org/10.1007/s40290-023-00504-9
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.